Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
Sucampo Pharmaceuticals Initiates Phase 2, Dose-Finding Trial of Cobiprostone for the Prevention of NSAID-Induced Ulcers in Arthritis Patients
October 5th, 2007
Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP), an emerging pharmaceutical company developing prostone-based therapies for age-related and other diseases, announced that it has enrolled the first patient in a multi-center Phase 2, dose-finding trial evaluating one of its clinical compounds, cobiprostone (SPI-8811), for the prevention of ulcers and other gastrointestinal injuries in arthritis patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). "While NSAIDs are among the most commonly used medications in the world, accounting for more than 70 million prescriptions in the U.S. alone, unfortunately these drugs also are responsible for significant...
Source: Health Business Week (2007-10-05)
|
